Navigation Links
Genetic Engineering & Biotechnology News reports on growing use of cell-based assays
Date:4/16/2008

New Rochelle, NY, April 16, 2008Biotech and pharma companies are increasingly relying on cell-based assays in early drug discovery work, reports Genetic Engineering & Biotechnology News (GEN). The technique can provide a quick and lower cost means of testing drug candidates for toxic effects, according to an article in the April 15 issue of GEN (http://www.genengnews.com/articles/chitem.aspx?aid=2437).

Better screening technologies, noninvasive monitoring, and more automation are driving the trend toward adoption of this technology, notes John Sterling, Editor-in-Chief of GEN. Some estimates project that the market for cell-based assays will more than double over the next six or seven years to over $230 million. This is definitely a methodology that should draw the interest of new drug developers.

More than 50% of currently marketed drugs target GPCRs, which impact a wide range of cellular processes. Multispan is looking to exploit this area and is collaborating with Promega and Molecular Devices to develop an array of applications for its GPCR cell-based assays.

Another field of much R&D interest involves protein-protein interactions. DiscoveRx created a new family of cell-based assays for the detection of protein-protein interactions using an enzyme fragment complementation assay. This system uses an enzyme acceptor, an inactive alpha-galactosidase enzyme that binds to its enzyme donor forming an active enzyme that will hydrolyze a substrate and provide a signal.


'/>"/>

Contact: Vicki Cohn
vcohn@liebertpub.com
914-740-2156
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Page: 1

Related biology news :

1. Does the desire to consume alcohol and tobacco come from our genetic makeup?
2. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
3. Many parents at-risk for cancer disclose genetic test results to children
4. Genetics determine optimal drug dose of common anticoagulant
5. Claims of sex-related differences in genetic association studies often not properly validated
6. American College of Medical Genetics responds to new FDA labeling decision for warfarin
7. UNC study questions FDA genetic-screening guidelines for cancer drug
8. Genome study shines light on genetic link to height
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
11. Rutgers Genetics receives $7.8 million for autism research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2017)... LAS VEGAS , Jan. 4, 2017 /PRNewswire/ ... in performance biometric sensor technology, today announced the ... Benchmark™ sensor systems, the highly-accurate biometric sensor ... ® biometric technology, experience and expertise. The ... of Benchmark designed specifically for hearables, and Benchmark ...
(Date:12/20/2016)... -- The rising popularity of mobility services such ... significant interest in keyless access systems. Following the ... (BLE), biometrics and near-field communication (NFC) are poised ... technologies in the automotive industry. This evolution from ... opens the market to specialist companies such as ...
(Date:12/16/2016)... Research and Markets has announced the addition ... to 2021" report to their offering. ... The biometric vehicle access system market, ... of 14.06% from 2016 to 2021. The market is estimated to ... 854.8 Million by 2021. The growth of the biometric vehicle access ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... , ... January 19, 2017 ... ... advanced software solutions for pharmaceutical research and development (R&D), today announced the ... omic data analysis and interpretation for the rapidly evolving field of precision ...
(Date:1/19/2017)... Bethesda, MD (PRWEB) , ... January 18, 2017 ... ... for the National Institutes of Health (NIH) to update its Data Sharing Policy. ... a “scoreable” element of grant applications subject to the existing policy. AMIA recommended ...
(Date:1/19/2017)...  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a ... operable and inoperable solid tumor cancers, announced today that ... NW Bio, will present at the Phacilitate Immunotherapy World ... Regency Hotel in Miami, Florida . ... "New Therapeutic Approaches – Expanding the Reach of Cancer ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical ... compounds designed to target cancer stemness pathways, will feature ... compound, napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, ... . Napabucasin is an orally-administered ... targeting STAT3. i Cancer stem cells (CSCs) possess ...
Breaking Biology Technology: